Patient and Family Care
Developing precisely controlled allogeneic cell therapies
with the potential to replace conventional bone marrow transplant
Orca Bio is a values-based company, deeply rooted in the principles of science and innovation and dedicated to transforming new ideas and discoveries into medicines for patients with serious illnesses. We founded Orca Bio on the belief that there is a more effective and compassionate way to target blood cancer and decrease transplant related mortalities. We put the needs of patients, families and healthcare providers at the center of everything we do.
Our Clinical Studies
The company’s most advanced clinical program, TRGFT-201, is evaluating a highly controlled cell mixture that includes subsets of regulatory T cells, in a large multi-center Phase I/II clinical trial in patients undergoing allogeneic transplantation for blood cancers. The company’s second clinical program, OGFT-001, is evaluating a fully controlled cell product candidate in a Phase I clinical trial, which is also in patients undergoing allogeneic transplantation for blood cancers.